EyePoint announced Thursday that an independent safety monitoring board discovered no fresh safety issues during their review of two advanced clinical trials testing an experimental vision treatment called Duravyu, giving the go-ahead for research to proceed as planned.
The medication under investigation targets wet age-related macular degeneration, commonly known as wet AMD, which represents a major source of sight deterioration among elderly individuals and can result in fuzzy vision or dark spots in central sight areas.
Safety monitors conducted their third planned assessment and determined the research should move forward without any modifications to study protocols.
According to EyePoint, preliminary results from the initial trial remain scheduled for mid-2026, while findings from the companion study are anticipated shortly thereafter.
The clinical trials have recruited more than 900 participants and are comparing Duravyu’s effectiveness against Regeneron’s established eye medication, Eylea.
EyePoint reported that preliminary safety information demonstrated a positive safety record, matching outcomes observed in over 190 participants from four previous studies.
Financial analysts from RBC Capital Markets stated the safety review met their predictions and boosted their confidence that repeated administration of EyePoint’s experimental treatment hasn’t created safety issues.
EyePoint explained the primary objective of these trials is to demonstrate that Duravyu performs comparably to Eylea in preserving patients’ eyesight at the 52 and 56-week marks.
The pharmaceutical company is also conducting advanced trials of the medication for diabetic macular edema, with results anticipated during the latter half of 2027.
In March, EyePoint initiated legal action against competitor Ocular Therapeutix, claiming the company made false statements regarding EyePoint and Duravyu.
